Newsroom | 209576 results
Sorted by: Latest
-
Pink Changing Lives®: Mary Kay realizza l'11° asilo nello Sri Lanka e trasforma un sogno in migliaia di nuovi inizi
DALLAS--(BUSINESS WIRE)--Mary Kay Inc., difensore globale dell'emancipazione femminile, ha scelto il rosa per passare all'azione tramite il suo programma Pink Changing Lives®, mirato ad aumentare la consapevolezza e a raccogliere fondi a sostegno di programmi che migliorano la vita e fanno avanzare la ricerca sul cancro, supportano le vittime di violenza domestica, tutelano le risorse più preziose del nostro pianeta e creano opportunità che contribuiscono alla prosperità delle donne e delle lor...
-
Pink Changing Lives®: Mary Kay constrói a 11a pré-escola no Sri Lanka, transformando um sonho em inúmeras novas oportunidades
DALLAS--(BUSINESS WIRE)--A Mary Kay Inc., defensora global do empoderamento feminino, está transformando a cor rosa em um propósito por meio do seu programa Pink Changing Lives®. O objetivo é aumentar a consciência e angariar fundos para financiar programas que impactam vidas, como pesquisas sobre o câncer, assistência a sobreviventes de violência doméstica, proteção de recursos mais valiosos do nosso planeta e criação de oportunidades que auxiliam mulheres e suas famílias a prosperar. Desde 19...
-
MedeAnalytics and Basys.ai Announce Strategic Partnership to Transform Healthcare Utilization Management, Improve MLR
RICHARDSON, Texas--(BUSINESS WIRE)--Healthcare data analytics leader MedeAnalytics and agentic AI innovator Basys.ai announced a strategic partnership that will benefit health payers....
-
BRUKINSA在初治慢性淋巴細胞白血病患者中取得里程碑式數據：六年無進展存活率達74%
加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球腫瘤治療創新公司BeOne Medicines Ltd.（Nasdaq: ONC; HKEX: 06160; SSE: 688235）在美國佛羅里達州奧蘭多舉行的第67屆美國血液學會（ASH）年會暨展覽會上展示公司血液學產品組合的深度、高品質和良好的發展趨勢，進一步證實了其在慢性淋巴細胞白血病（CLL）創新治療領域的領先地位。BeOne在ASH大會上展示的資料進一步證實了BRUKINSA ®（澤布替尼）可作為治療首選的基石性布魯頓氏酪胺酸激酶抑制劑（BTK抑制劑）。 BeOne副總裁暨血液學醫學長、醫學博士Amit Agarwal表示：「我們在2025年ASH大會上所展示的CLL產品組合新資料展現了BRUKINSA的實力和BGB-16673的潛力。長期數據是CLL治療的黃金標準，BRUKINSA持續展現出高水平的持久無進展生存期和總生存期特徵，符合患者和醫生對BTK抑製劑的期待。BGB-16673是目前臨床開發進展最快的BTK降解劑，已有800多例患者接受給藥。這款藥物有望引領腫瘤治療領域新一波創新。」 在超過...
-
LifeScan Successfully Emerges from Financial Restructuring Process, Enters Next Chapter with Renewed Strength
MALVERN, Pa.--(BUSINESS WIRE)--LifeScan (the “Company”), a world leader in blood glucose monitoring, today announced its successful emergence from its Chapter 11 financial restructuring process following approval of its Plan of Reorganization on October 27, 2025. Through this process, the Company eliminated more than 75% of its debt, providing the financial flexibility needed to continue its leadership in the glucose management industry. In connection with emergence, LifeScan is now owned by a...
-
Samenvatting: BRUKINSA behaalt een baanbrekende, zesjarige progressievrije overleving van 74% bij patiënten met behandelingsnaïeve chronische lymfatische leukemie (CLL)
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een mondiaal oncologisch bedrijf, herbevestigt zijn positie als leider in innovaties voor chronische lymfatische leukemie (CLL) door de breedte, kwaliteit en het momentum van zijn hematologisch portfolio te demonstreren op de 67ste jaarlijkse vergadering en expositie van ASH in Orlando, Florida. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp...
-
Riassunto: BRUKINSA offre ai pazienti affetti da leucemia linfatica cronica naive al trattamento un risultato storico con una PFS (sopravvivenza libera da progressione) a 6 anni del 74%
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda farmaceutica oncologica globale, riafferma la sua posizione come leader innovativo nella leucemia linfatica cronica (LLC) mostrando la profondità, la qualità e lo slancio del suo portafoglio ematologico al 67o Meeting annuale ed Esposizione dell'American Society of Hematology (ASH) a Orlando, Florida. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione...
-
From Novel Therapies to First-in-Human Trials, City of Hope Advances Blood Cancer Care at the American Society of Hematology (ASH) Annual Conference
LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, presented scientific results on novel therapies, treatment strategies, and approaches to managing side effects and complications for blood cancer patients at the 2025 American Society of Hematology (ASH) conference in Orland...
-
Les données sur le sonrotoclax présentées à l'ASH 2025 confirment le potentiel fondamental sur l'ensemble des tumeurs malignes à cellules B
SAN CARLOS, Californie--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société mondiale d'oncologie, annonce aujourd'hui de nouvelles données sur le sonrotoclax, un inhibiteur de BCL2 expérimental de nouvelle génération, démontrant un bénéfice clinique significatif en monothérapie et en combinaison contre des tumeurs malignes à cellules B. Ces données ont été présentées lors de la 67e réunion annuelle de l'American Society of Hematology (ASH) à Orlando,...
-
ASH 2025で発表されたソンロトクラックスのデータ、B細胞悪性腫瘍全体での基盤的治療薬となる可能性を確認
カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルなオンコロジー企業であるBeOne Medicines Ltd.（Nasdaq: ONC、HKEX: 06160、SSE: 688235）は、次世代の治験中BCL2阻害薬であるソンロトクラックスについて、B細胞悪性腫瘍全体にわたり単剤療法および併用療法のいずれにおいても臨床的に意義のある有益性を示した新たなデータを発表しました。これらのデータは、フロリダ州オーランドで開催された第67回米国血液学会（ASH）年次総会・展示会で発表されました。今回の5件の発表では、前治療歴の多い再発／難治性（R/R）マントル細胞リンパ腫（MCL）患者における持続的な奏効に加え、未治療の慢性リンパ性白血病（CLL）患者においてソンロトクラックスをベースとする併用療法により、深く迅速かつ持続的な検出不能微小残存病変（uMRD）の達成率が示されており、本剤がB細胞悪性腫瘍における基盤的治療薬となる可能性を浮き彫りにしています。 「今回、ASH 2025で発表しているデータは、次世代BCL2阻害薬としてのソンロ...
